Full-Time

Encryption Agility Engineer

Trusted Core Technologies

Updated on 9/10/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's, Master's, PhD

Category
Cybersecurity (1)
Required Skills
LLM
PowerShell
Bash
Fortinet
Python
ServiceNow
Data Engineering
AWS
Cryptography
HashiCorp Vault
REST APIs

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A doctorate degree in Information Security, Cybersecurity, Cryptography, Security Architecture, Computer Science, Information Technology, Engineering, or a related field; or a master's degree with 4 to 6 years of experience; or a bachelor's degree with 6 to 8 years of experience; or a diploma with 10 to 12 years of experience in these fields.
  • Strong hands-on knowledge of enterprise cryptography, including Public Key Infrastructure, X.509 certificates, Transport Layer Security, cipher suites, Key Management Services, Hardware Security Modules, secrets management, key lifecycle, encryption at rest, encryption in transit, cloud key services, identity protocols, and certificate lifecycle automation.
  • Practical experience with cryptographic discovery, Cryptographic Bill of Materials-driven inventory, source code scanning, network and endpoint telemetry, cloud key service analysis, false-positive triage, data quality controls, dashboards, and remediation tracking.
  • Working knowledge of post-quantum cryptography, crypto agility, NIST-approved algorithms and standards, hybrid transition patterns, Steal-Now-Decrypt-Later risk reduction, and risk-prioritized remediation.
  • Ability to convert cryptographic policy, architecture direction, and scan findings into actionable engineering guidance across Continuous Integration/Continuous Delivery, Secure Software Development Life Cycle, cloud platforms, Public Key Infrastructure and certificates, Key Management Services and secrets, identity, infrastructure, applications, third-party governance, and risk management.
  • Mandatory experience designing and implementing Artificial Intelligence-enabled process orchestration for security, cryptography, governance, risk, compliance, or technology-operations workflows, including AI agents or multi-agent patterns and human-in-the-loop review for high-risk activities.
  • Mandatory ability to architect AI agents through workflow decomposition, agent role definition, tool and data-source integration, prompt and instruction design, validation checkpoints, exception handling, auditability, and escalation paths for human review.
  • Strong analytical, troubleshooting, and problem-solving skills.
  • Strong technical ownership and ability to drive complex discovery, analysis, and remediation work to completion.
  • Strong verbal and written communication skills for technical, business, compliance, procurement, and vendor audiences.
  • Ability to translate cryptographic findings into clear risk statements, remediation options, and implementation steps.
  • Ability to influence without direct authority across global security, Digital, Technology and Innovation, Digital Identity Access Service, procurement, legal, compliance, Operational Technology, infrastructure, cloud, and application teams.
  • Strong coaching and mentoring skills for L4 analysts and technical contributors.
  • Strong documentation, presentation, and knowledge-sharing skills for technical reviews, service updates, and architecture forums.
  • Strong ability to identify manual process bottlenecks, redesign workflows for automation and AI augmentation, and balance productivity improvement with quality, accountability, and human judgment.
Responsibilities
  • Execute assigned Encryption Agility Service workstreams, including intake analysis, backlog execution, roadmap tracking, service metrics, reporting inputs, Standard Operating Procedure updates, and service improvement actions under the direction of the Senior Manager and Principal Architect.
  • Operate enterprise cryptographic discovery across source code, binaries, cloud key services, endpoints, file systems, network traffic, Public Key Infrastructure and certificates, Key Management Services and secrets, vendor attestations, Software Bill of Materials inputs, and Subject Matter Expert interviews.
  • Build, maintain, and improve the Amgen Cryptographic Bill of Materials using CycloneDX 1.6 or later as the target format, including required fields, source systems, ownership attributes, quantum-vulnerability status, remediation status, data quality checks, reporting views, and asset correlation.
  • Support tool integration and data normalization across Amgen Enterprise and cryptographic discovery platforms.
  • Analyze cryptographic scan outputs, source code findings, certificate chains, cipher suite configurations, Transport Layer Security settings, Secure Shell settings, Open Authorization, Security Assertion Markup Language, JSON Web Token patterns, cloud key configurations, and key or secret storage patterns.
  • Implement and document approved remediation patterns, including hybrid Transport Layer Security, proxy-based crypto agility, network encapsulation, Internet Protocol Security, Media Access Control Security, Key Management Interoperability Protocol, Public-Key Cryptography Standard number 11, provider libraries, custom code libraries, symmetric cryptography, Hash-Based Message Authentication Code, Transport Layer Security termination, reverse proxies, encrypted overlays, segmentation controls, compensating controls, and risk-based replacement or decommission pathways.
  • Coordinate with identity, Public Key Infrastructure, certificate management, cloud, infrastructure, and platform teams on certificate visibility, Certificate Lifecycle Manager evaluation, certificate rotation, deployment automation, post-quantum Public Key Infrastructure readiness, hybrid certificate testing, Certificate Authority modernization, Key Management Services strategy, Hardware Security Module patterns, secrets management, key rotation, key retirement, storage standards, ownership, reporting, and centralized or federated control options.
  • Partner with Application Security, Artificial Intelligence Security, Enterprise Architecture, Development and Operations, and engineering teams to publish approved cryptographic libraries, secure code examples, reusable patterns, Continuous Integration/Continuous Delivery controls, Secure Software Development Life Cycle requirements, scanning rules, developer remediation playbooks, and implementation guidance.
  • Apply Amgen's quantum risk-prioritization approach to discovery and remediation planning for business-critical applications, sensitive data flows, third-party dependencies, identity services, legacy platforms, Key Computerized Systems, validated Good x Practice systems, and Operational Technology scope.
  • Support vendor and third-party technical governance by preparing technical questionnaire content, Cryptographic Bill of Materials requests, evidence reviews, roadmap tracking, contract-language inputs, escalation triggers, and supplier remediation follow-up.
  • Provide technical escalation and mentoring for Global Career Framework level 4 analysts and contributors, maintain cryptographic knowledge articles and implementation guides, and track changes in relevant cryptography guidance.
  • Design, implement, and govern Artificial Intelligence-enabled process orchestration for Encryption Agility Service workflows, including inventory analysis, Cryptographic Bill of Materials data normalization, scan-output review, evidence collection, remediation tracking, reporting, and governance workflows; architect AI agents or coordinated AI-agent teams for data ingestion, finding correlation, false-positive triage support, ownership enrichment, remediation recommendation drafting, dashboard preparation, and knowledge-article generation while ensuring human-in-the-loop controls for risk decisions, exceptions, production changes, and final approvals.
Desired Qualifications
  • Hands-on experience with ServiceNow Configuration Management Database and Governance, Risk, and Compliance, Guard, Wiz, Qualys, Fortinet, Netskope, CrowdStrike, GitLab, Veracode, GitGuardian, Amazon Web Services Key Management Services, AWS Certificate Manager, AWS Secrets Manager, Microsoft Public Key Infrastructure, Sectigo, HashiCorp Vault, Hardware Security Modules, Certificate Lifecycle Management platforms, and Security Information and Event Management or data-lake integrations.
  • Experience creating or operating Cryptographic Bill of Materials or Software Bill of Materials data models using CycloneDX 1.6 or later, Application Programming Interfaces, Comma-Separated Values, JavaScript Object Notation, dashboards, data quality checks, and audit-ready reporting.
  • Experience with Public Key Infrastructure modernization, certificate automation, certificate rotation, Certificate Authority hierarchy changes, hybrid certificate testing, and Post-Quantum Public Key Infrastructure transition support.
  • Experience with key management and secrets management across AWS, Azure, on-premises platforms, Hardware Security Modules, vault technologies, automation workflows, and centralized or federated operating models.
  • Experience with application security, Development and Operations, Secure Software Development Life Cycle governance, Continuous Integration/Continuous Delivery quality gates, approved cryptographic libraries, static analysis, dynamic analysis, composition analysis, and developer enablement.
  • Experience in pharmaceutical, life sciences, regulated, validated, Good x Practice, Key Computerized Systems, manufacturing, Operational Technology, or other change-controlled environments.
  • Scripting and automation experience with Python, PowerShell, Bash, Representational State Transfer Application Programming Interfaces, data pipelines, parsing of certificate or scan data, or lightweight integration development.
  • Certified Information Systems Security Professional certification.
  • Certified Cloud Security Professional, AWS Certified Security Specialty, Microsoft Azure Security Engineer, or equivalent cloud security certification.
  • Certified Information Security Manager, Certified Information Systems Auditor, or Certified in Risk and Information Systems Control certification.
  • Security+ or Systems Security Certified Practitioner certification.
  • Relevant Public Key Infrastructure, Key Management Services, Hardware Security Module, cryptographic discovery, certificate lifecycle management, cloud key management, or post-quantum cryptography training or certification.
  • Ability to work collaboratively, take initiative, exercise accountability and judgment, and operate effectively in ambiguous or evolving technical domains.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $38.2 billion-$39.4 billion.
  • Repatha sales jumped 37% to $953 million in Q2 2026, with U.S. prescriptions up 50%.
  • MariTide advanced through multiple Phase 3 studies in 2026, supporting a 2027 obesity catalyst.

What critics are saying

  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy cash cow.
  • FDA proposed withdrawing Tavneos in April 2026, signaling regulatory risk from integrity and efficacy issues.
  • Olpasiran now faces Novartis pelacarsen failure scrutiny; a negative 2028 OCEAN(a) readout would crush Lp(a) upside.

What makes Amgen unique

  • Repatha, Evenity, and Uplizna diversify Amgen beyond one blockbuster, per August 2026 sales.
  • MariTide targets quarterly or eight-week dosing, unlike Lilly and Novo Nordisk weekly injections.
  • Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-enabled drug discovery globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.

Yahoo Finance
Sep 7th, 2026
Amgen's $437 olpasiran bet faces higher bar after Novartis Lp(a) drug fails Phase 3 trial

Amgen faces heightened scrutiny for its experimental heart drug olpasiran after rival Novartis's pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial, despite successfully lowering lipoprotein(a) levels. The setback demonstrates that improving laboratory biomarkers may not translate to better patient outcomes. Amgen's OCEAN(a) outcomes study has enrolled 7,297 participants and is tracking heart-related deaths and procedures over roughly five years. While olpasiran uses a different design and may target different patients, pelacarsen's failure removes assumptions about the commercial value of lowering Lp(a). Amgen's shares traded at $437.23, sitting 19.54% above its estimated fair value of $365.76. The company reported $10.1 billion in second-quarter revenue and $3.5 billion in free cash flow.

Yahoo Finance
Sep 1st, 2026
Amgen's Repatha hits $953M in Q2 sales, up 37% as Cramer calls it "biggest market of all time

Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.